These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724 [TBL] [Abstract][Full Text] [Related]
4. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Wagstaff AJ; Frampton JE; Croom KF Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096 [TBL] [Abstract][Full Text] [Related]
6. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051 [TBL] [Abstract][Full Text] [Related]
7. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Baker DE Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185 [TBL] [Abstract][Full Text] [Related]
8. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome. Beglinger C Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835 [TBL] [Abstract][Full Text] [Related]
10. A systematic review of tegaserod for the treatment of irritable bowel syndrome. Jones BW; Moore DJ; Robinson SM; Song F J Clin Pharm Ther; 2002 Oct; 27(5):343-52. PubMed ID: 12383135 [TBL] [Abstract][Full Text] [Related]
11. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251 [TBL] [Abstract][Full Text] [Related]
12. Update on irritable bowel syndrome. Bergmann KA Postgrad Med J; 2003 Dec; 79(938):715. PubMed ID: 14707260 [No Abstract] [Full Text] [Related]
13. Novel medications for the irritable bowel syndrome: motility and sensation. Camilleri M J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419 [No Abstract] [Full Text] [Related]
14. New drug approved for irritable bowel syndrome in women. Mayo Clin Womens Healthsource; 2004 Feb; 8(2):3. PubMed ID: 14722489 [No Abstract] [Full Text] [Related]
15. Review of tegaserod in the treatment of irritable bowel syndrome. Patel S; Berrada D; Lembo A Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384 [TBL] [Abstract][Full Text] [Related]
16. [Tegaserod in treatment of women with irritable bowel syndrome]. Munck LK; Ainsworth MA Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683 [TBL] [Abstract][Full Text] [Related]
17. Tegaserod and IBS: a perfect match? Grant Thompson W Gut; 2003 May; 52(5):621-2. PubMed ID: 12692042 [No Abstract] [Full Text] [Related]
18. [New drug for irritable bowel syndrome]. Hennemann A Med Monatsschr Pharm; 2001 Apr; 24(4):106-8. PubMed ID: 11338633 [No Abstract] [Full Text] [Related]
19. [Diets in irritable bowel syndrome--what do they really achieve? Please no culinary sadism!]. Stiefelhagen P MMW Fortschr Med; 2001 Nov; 143(46):18. PubMed ID: 11759593 [No Abstract] [Full Text] [Related]